Peter F A Mulders Selected Research

G250 monoclonal antibody

1/2021	Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma.
1/2020	Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.
1/2018	Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
1/2016	Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
1/2016	Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
2/2015	Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
6/2014	Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
2/2014	Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
10/2013	Reply to John Samuel Banerji's letter to the editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63:1101-6.
9/2013	Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter F A Mulders Research Topics

Disease

42	Renal Cell Carcinoma (Grawitz Tumor) 05/2022 - 02/2002
35	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 02/2007
31	Neoplasms (Cancer) 05/2022 - 11/2002
8	Neoplasm Metastasis (Metastasis) 07/2018 - 05/2009
3	Kidney Neoplasms (Kidney Cancer) 01/2016 - 10/2011
3	Disease Progression 01/2015 - 09/2005
2	Margins of Excision 02/2019 - 08/2015
2	Lymphatic Metastasis 07/2017 - 05/2009
2	Carcinoma (Carcinomatosis) 01/2017 - 01/2016
2	Heart Diseases (Heart Disease) 11/2015 - 02/2015
2	Cancer Pain 10/2015 - 01/2013
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 10/2017
1	Neoplasm Micrometastasis 01/2017
1	Colorectal Neoplasms (Colorectal Cancer) 01/2017
1	Diarrhea 01/2016
1	Thrombosis (Thrombus) 01/2016
1	Thrombocytopenia (Thrombopenia) 01/2016
1	Heartburn (Pyrosis) 01/2016
1	Duodenitis 01/2016
1	Flatulence 01/2016
1	Colic (Abdominal Cramps) 01/2016
1	Hypertension (High Blood Pressure) 02/2015
1	Necrosis 02/2015
1	Nausea 01/2015
1	Fatigue 01/2015
1	Seizures (Absence Seizure) 01/2015
1	Pain (Aches) 11/2014
1	Ascites 07/2011
1	Human Influenza (Influenza) 07/2011

Drug/Important Bio-Agent (IBA)

17	Carbonic Anhydrase IXIBA 05/2022 - 09/2003
14	G250 monoclonal antibodyIBA 01/2021 - 09/2003
12	Abiraterone AcetateIBA 07/2018 - 01/2013
11	Monoclonal AntibodiesIBA 01/2018 - 09/2005
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2014
10	AntigensIBA 01/2017 - 07/2003
9	Prostate-Specific Antigen (Semenogelase)IBA 12/2020 - 02/2007
6	Prednisone (Sone)FDA LinkGeneric 07/2017 - 01/2013
6	AntibodiesIBA 01/2016 - 07/2003
6	Sorafenib (BAY 43-9006)FDA Link 03/2014 - 01/2009
5	Radioisotopes (Radionuclides)IBA 05/2022 - 09/2003
5	AndrogensIBA 01/2017 - 01/2013
5	Tyrosine Kinase InhibitorsIBA 01/2016 - 04/2008
5	Sunitinib (Sutent)FDA Link 02/2015 - 01/2009
4	Messenger RNA (mRNA)IBA 01/2022 - 09/2014
4	enzalutamideIBA 07/2018 - 01/2015
4	Proteins (Proteins, Gene)FDA Link 10/2017 - 07/2003
3	LutetiumIBA 01/2016 - 09/2013
3	Docetaxel (Taxotere)FDA Link 01/2015 - 05/2014
2	Fluorescent Dyes (Fluorescent Probes)IBA 10/2017 - 01/2016
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2016 - 11/2010
2	Dutasteride (Avodart)FDA Link 01/2016 - 11/2009
2	Indium-111IBA 01/2016 - 06/2013
2	Opiate AlkaloidsIBA 10/2015 - 01/2013
2	Testosterone (Sustanon)FDA Link 01/2015 - 07/2013
2	abirateroneIBA 11/2014 - 01/2013
2	Interleukin-2 (IL2)IBA 02/2010 - 11/2002
2	Dihydrotachysterol (AT 10)IBA 12/2009 - 02/2009
1	Lutetium-177IBA 05/2022
1	Actinium-225IBA 05/2022
1	Immunoconjugates (Immunoconjugate)IBA 05/2022
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 12/2018
1	Denosumab FDA Link 07/2018
1	Radium-223IBA 07/2018
1	Diphosphonates (Bisphosphonates)IBA 07/2018
1	Cell-Free Nucleic AcidsIBA 01/2018
1	farletuzumabIBA 10/2017
1	Folate Receptor 1IBA 10/2017
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2017
1	labetuzumabIBA 01/2017
1	SuspensionsIBA 01/2017
1	AcidsIBA 01/2017
1	Everolimus FDA Link 04/2016
1	NivolumabIBA 04/2016
1	bicalutamide (Casodex)FDA LinkGeneric 01/2016
1	Capsules (Microcapsules)IBA 01/2016
1	Pentetic Acid (DTPA)FDA LinkGeneric 08/2015
1	Alanine Transaminase (SGPT)IBA 02/2015
1	Hormones (Hormone)IBA 01/2015
1	Coloring Agents (Dyes)IBA 06/2014
1	N 30IBA 03/2014
1	IndiumIBA 09/2013

Therapy/Procedure

18	Therapeutics 05/2022 - 09/2003
16	Castration 07/2018 - 01/2013
10	Drug Therapy (Chemotherapy) 07/2017 - 11/2007
8	Nephrectomy 02/2019 - 02/2002
6	Immunotherapy 01/2019 - 02/2002
6	Radioimmunotherapy 01/2016 - 09/2005
3	Aftercare (After-Treatment) 01/2017 - 01/2012
2	Life Support Care 10/2015 - 11/2014
2	Neoadjuvant Therapy 07/2011 - 11/2010
1	Prostatectomy (Retropubic Prostatectomy) 11/2020
1	Cryosurgery 01/2020
1	Cystectomy 01/2019
1	Conservative Treatment 08/2018
1	Intravenous Injections 01/2017
1	Retreatment 01/2016
1	Duration of Therapy 01/2016
1	Drug Tapering 11/2015
1	Computer-Assisted Surgery (Image Guided Surgery) 08/2015